Results 321 to 330 of about 467,565 (384)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

Clinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez, George S. Q. Tan, Sam Wade, Zanfina Ademi, Jenni Ilomäki, J. Simon Bell   +5 more
wiley   +1 more source

Nonsustained Atrial Fibrillation in Ambulatory ECG Recording and Thromboembolic Events in Long term Follow-Up. [PDF]

Anatol J Cardiol
Yurtseven E, Ural D, Karaüzüm K, Yılmaz İ, Çelikyurt YU, Hancı K, Aktaş M, Sinan ÜY, Küçükoğlu S, Ağaçdiken Ağır A.   +9 more
europepmc   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Risk of bleeding with dentoalveolar surgery in patients taking direct oral anticoagulants or vitamin K antagonists: A systematic review and meta-analysis. [PDF]

Jpn Dent Sci Rev
Dou K, Shi Y, Yang B, Zhao Z.
europepmc   +1 more source

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang, Kevin J. O'Leary, Edith A. Nutescu, Matthew Jack, Thomas Chen, Gregory W. Ruhnke, James C. Lee, David George, Larry K. House, Randall Knoebel, Luke V. Rasmussen, Seth Hartman, Anish Choksi, Kiang‐Teck J. Yeo, Minoli A. Perera, Mark J. Ratain, David O. Meltzer, Peter H. O'Donnell   +17 more
wiley   +1 more source

To anticoagulate or not to anticoagulate-that is the question in patients with fall risks. [PDF]

Res Pract Thromb Haemost
Wang TF.
europepmc   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source

Anticoagulation Therapy and Severe Traumatic Brain Injury: A Retrospective Cohort Study on Clinical Outcomes Using TriNetX. [PDF]

J Clin Med
Rasmussen S, Shaik K, Rawson C, Saloum A, Rahme R, Karsy M.   +5 more
europepmc   +1 more source